الفهرس 
Spontaneous Bacterial PeritonitisOnly 14 pages are availabe for public view
 |  | from | 199 |  |  |
| | | from | 199 | | |
Abstract
Spontaneous bacterial peritonitis (SBP) is the most frequent and life-threatening infection in patients with liver cirrhosis requiring prompt recognition and treatment. This study was directed to evaluate the role of sparfloxacin and pentoxifylline in the prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients. Patients were assessed by clinical examination, liver and renal function tests, complete blood picture and serum tumor necrosis factor alpha (TNF-α) level. There were no differences in baseline characteristic among all involved groups. Patients were physically examined for any signs or symptoms of abdominal tenderness and fever. There was no significant difference in clinical manifestations among patients in the studied groups. Serum TNF–α level was the primary inflammatory marker of the study to evaluate the effect of the used medications. In group two, TNF-α level showed a statistically significant decrease compared to group one (P =0.001) while in group three, TNF-α level showed non-significant difference in comparing with control group (P >0.05). In addition, group four showed a statistically significant decrease in TNF-α level in comparison with the other three groups (P <0.05) According to the data obtained by this study, sparfloxacin could be used in prophylaxis of spontaneous bacterial peritonitis due to its broad
spectrum of activity against Gram-positive and Gram-negative bacteria and some anaerobes. Pentoxifylline as tumor necrosis factor inhibitor could be another promising approach reported to hinder BT and to be used as prophylactic therapy agent for spontaneous bacterial peritonitis.